Fidelity International
IOVA icon

Fidelity International’s Iovance Biotherapeutics IOVA Stock Holding History

Fidelity International’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-154
Closed -$5K – 998
2020
Q3 		$5K Hold
154
– – ﹤0.01% 786
2020
Q2 		$4K Hold
154
– – ﹤0.01% 779
2020
Q1 		$5K Sell
154
-69
-31% -$1.83K ﹤0.01% 724
2019
Q4 		$6K Buy
+223
New +$5.07K ﹤0.01% 765
2018
Q4 		– Sell
-1,336,179
Closed -$15M – 903
2018
Q3 		$15M Buy
+1,336,179
New +$19M 0.02% 429

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity International's IOVA Position: Q4 2020 in Review

Fidelity International sold out of Iovance Biotherapeutics (IOVA) in Q4 2020, closing a stake of 154 shares — an estimated $5K sold.

Fidelity International first reported a position in IOVA in Q3 2018 and held it in 5 quarters. The position peaked at $15M in Q3 2018. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

  • Fidelity International reported no remaining Iovance Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Fidelity International sold 154 Iovance Biotherapeutics shares in Q4 2020, an estimated $5K.
  • Fidelity International first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 5 quarters.
  • Fidelity International's Iovance Biotherapeutics position peaked at $15M in Q3 2018.
  • 269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on Fidelity International's 13F filing for Q4 2020, filed 8 Feb 2021.